Acute Myeloid Leukemia Clinical Trial

A Long-term Follow-up Study of Patients Who Received VOR33

Summary

VOR33 long-term follow-up (LTFU) study

View Full Description

Full Description

VBP201 study is the VOR33 long-term follow-up (LTFU) study focusing on assessing long term safety and efficacy of VOR33. This study may last up to 15 years (counted from the date of VOR33 infusion completion). All patients who have participated in a study involving the drug product VOR33 and have completed the applicable study or prematurely discontinued, but have at least received the VOR33 infusion, will be asked to participate in the LTFU study.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

A patient is included in this study if he/she:

Has received any part of or all of a VOR33 infusion

Exclusion Criteria:

There are no exclusion criteria.

Study is for people with:

Acute Myeloid Leukemia

Estimated Enrollment:

36

Study ID:

NCT05309733

Recruitment Status:

Recruiting

Sponsor:

Vor Biopharma

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 9 Locations for this study

See Locations Near You

University of California San Diego Moores Cancer Center
La Jolla California, 92037, United States More Info
Michelle Padilla
Contact
858-822-5364
[email protected]
Divya Koura, MD
Principal Investigator
Miami Cancer Institute
Miami Florida, 33176, United States More Info
Guenther Koehne, MD, PhD
Contact
786-527-8427
[email protected]
Guenther Koehne, MD, PhD
Principal Investigator
Washington University School of Medicine Siteman Cancer Center
Saint Louis Missouri, 63110, United States More Info
Cathy Wiggins
Contact
314-454-8491
[email protected]
John DiPersio, MD
Principal Investigator
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack New Jersey, 07601, United States More Info
Hyung Suh, MD
Contact
551-996-5863
[email protected]
Hyung Suh, MD
Principal Investigator
Columbia University Medical Center - Herbert Irving Comprehensive Cancer Center
New York New York, 10032, United States More Info
Nurse Navigator
Contact
212-342-5162
[email protected]
Markus Y Mapara, MD, PhD
Principal Investigator
Memorial Sloan Kettering Cancer Center
New York New York, 10065, United States More Info
Christina Cho, MD
Contact
646-608-3785
[email protected]
Christina Cho, MD
Principal Investigator
University Hospitals Seidman Cancer Center
Cleveland Ohio, 44106, United States More Info
Cancer Information Service Line
Contact
800-641-2422
[email protected]
Brenda Cooper, MD
Principal Investigator
Fred Hutchinson Cancer Research Center
Seattle Washington, 98109, United States More Info
Roland Walter, MD, PhD, MS
Contact
[email protected]
Roland Walter, MD, PhD, MS
Principal Investigator
Hôpital Maisonneuve-Rosemont
Montréal Quebec, H1T 2, Canada More Info
Nadia Bambace, MD
Contact
514-252-3404
[email protected]
Nadia Bamace, MD
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Acute Myeloid Leukemia

Estimated Enrollment:

36

Study ID:

NCT05309733

Recruitment Status:

Recruiting

Sponsor:


Vor Biopharma

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider